Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants

COVID-19 pandemic has severely impacted the public health and social economy worldwide. A safe, effective, and affordable vaccine against SARS-CoV-2 infections/diseases is urgently needed. We have been developing a recombinant vaccine based on a prefusion-stabilized spike trimer of SARS-CoV-2 and fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haitao, Zhou, Chenliang, An, Jiao, Song, Yujiao, Yu, Pin, Li, Jiadai, Gu, Chenjian, Hu, Dongdong, Jiang, Yuanxiang, Zhang, Lingli, Huang, Chuanqi, Zhang, Chao, Yang, Yunqi, Zhu, Qianjun, Wang, Dekui, Liu, Yuqiang, Miao, Chenyang, Cao, Xiayao, Ding, Longfei, Zhu, Yuanfei, Zhu, Hua, Bao, Linlin, Zhou, Lingyun, Yan, Huan, Fan, Jiang, Xu, Jianqing, Hu, Zhongyu, Xie, Youhua, Liu, Jiangning, Liu, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556577/
https://www.ncbi.nlm.nih.gov/pubmed/34750014
http://dx.doi.org/10.1016/j.vaccine.2021.10.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556577/
https://www.ncbi.nlm.nih.gov/pubmed/34750014
http://dx.doi.org/10.1016/j.vaccine.2021.10.066

Ejemplares similares